Show notes
In the second episode of this two-part series, Dr. Stacey Clardy talks with Dr. Justin Abbatemarco about the risks of immunosuppression for autoimmune neurologic diseases and how to optimize the benefits of immunotherapies while minimizing the associated risks.
Read the related article in Neurology®.
Disclosures can be found at Neurology.org.
________________________________________________
Dr. Jose Merino: This is Jose Merino, editor-in-chief of the Neurology Family of Journals. The Neurology Podcast provides practical information to neurologists and other clinicians to help them provide better care for their patients. Thanks for listening, and have a great week.
Dr. Stacey Clardy: This is Stacey Clardy from the Salt Lake City VA, back with part two of our Bugs and Drugs in the B-cell Era Depletion podcast with Justin Abbatemarco. We're talking about things that have come to the forefront in terms of infections and how they present and how to prevent them in B-cell depleted patients, but also as it applies to folks with immunocompromise of all varieties. We discussed specifically the Potosi virus in part one, and here we're going to talk more broadly about common viruses that our patients encounter and how we address this, what we can do to prevent things, and cautions around making sure patients are vaccinated, but being careful with those live vaccines as well. I hope you enjoy. Justin, how do you approach, first of all, anti-CD20 dosing, or what can you do to mitigate the effects of any therapy? And how do you feel about the possible role of immune globulin treatment here?
Dr. Justin Abbatemarco: It's such a challenging scenario, and sometimes asking for some help with our colleagues, allergy and immunology is a big part of our practice here. And asking whether or not possibly supplementing with IVIG, if especially their IG levels are low, is something to at least think about. As you've talked about in the podcast many times, we should get all of the samples that we need, both in serum and CSF before initiating IVIG because it can cloud all of those results. And so saving those samples beforehand. And also again, acknowledging that there's not great data to help support this. Maybe the best data is within the West Nile literature that it's possible IVIG, especially if it's pooled around that area, might have relevant autoantibodies to help that patient fight off infection, and was published in some of the reports you've already mentioned. And to see if that would offer any chance, again, in these really challenging spots where we don't have effective vaccinations, we don't have effective antivirals, and how are we going to help patients? It's a multidisciplinary discussion. How do you think about it in your practice?
Dr. Stacey Clardy: The same, really. We're in autoimmuneology, so we're accustomed to having discussions where there isn't high-quality data. We all are equally frustrated by the fact that usually at best we can discuss low-quality case series, retrospective studies. And so I explain that whole concept of what I'm coming to the table with, to the family and to the patient, and say, "This is low-quality data. I want you to know that," so that they understand the level I'm presenting and the level they're making a decision with. Of course, yes, always preserving those samples and the ability to hopefully find out in the future more of what's going on. But when you're in the hospital, when you're ill, when you're decompensating, those specific patients, yeah, certainly we have for West Nile cases given intravenous immunoglobulin as part of supportive care, but full well acknowledging to everyone, the family, the patient if they're well enough, the teams, this is a bit of a Hail Mary, and it's theoretical, just hoping that particular donor pool might be able to offer some prior infectious exposure immunity to the patient that's receiving that. So yeah, pretty much the same as you, I would say. And you're making me think back to what you said about vaccines. That's a fraught discussion and one where I have had to do a lot of education to two big points that I always have to refresh on. One, we can't do live vaccines after they're on that B-cell therapy. And the other one is counseling patients on what vaccinations actually do. And this one's coming up now because here we are November. So I've been having the influenza vaccine talk at every single visit. And many patients say, "Okay, I'll get the flu shot because I don't want to get the flu." And I immediately pause the conversation, and I say, "Look, that's not what this vaccine does. You are still going to get the flu if you're exposed to the flu virus in the sufficient environment, in the sufficient amount." I say, "Our goal here," particularly for those on immunosuppression, "our goal here is that if you are vaccinated, we hopefully keep you out of the hospital. We're hopefully lessening the severity of the infection that you are going to get if you're exposed in the appropriate setting." And it's amazing to me that the large majority of folks forget that. I don't know if that's your experience.
Dr. Justin Abbatemarco: The same exact experience. I wish I could just have my answer on a loop just so I could help, but it's an important conversation we have to have. The other thing that came to mind was patients saying that before they were on treatment, "I never got the flu and so I don't need the vaccine," and trying to shift their mindset to be like, "Absolutely, hear that, but your risk profile has profoundly shifted now." We've got to change that thought process a little bit. And yes, that when you get the vaccine, you might not feel well for a few days, but much better than going to the hospital or even worse outcomes that we know can be associated with flu and other bugs.
Dr. Stacey Clardy: And particularly around the holidays, it becomes a perfect storm. And so I do try to acknowledge this in some of our conditions more than others that I jokingly say, "Hey, you have a doctor's note from me not to spend any time with anyone who stresses you out around the holidays." Because it's also that everything that happens when people holiday, so sleep disruption, poor diet, and probably most importantly, the emotional stressors that have impacts on the immune system that we don't even begin to understand, except that we see it. We see that patients do worse with autoimmune conditions when they take those emotional hits. I believe my patients, they go to a stressful funeral, and that's their first symptom. So I try to give them this whole package of a talk and say, look, if they stress you out anyway, if they tell you they have a sniffle, that's a no-go because you put the perfect storm together, you're going to get sick, even if you do some Purell and things like that. So take yourself out of those situations. And usually, it's at least good for a bit of a chuckle from the patients, but also I hope that they're internalizing that into the entire, to your point, lifestyle. This is a different you. This isn't the you that never got the flu before you were immunocompromised. This is a new you and one where you have to pay attention not just to the germs, but the entire setting around that. I don't know if you do anything like that, but it at least helps sometimes, hopefully, to lighten the mood.
Dr. Justin Abbatemarco: I was going to say, it feels like it's going to become like an in-laws talk. I don't know how those conversations to help or is the smart phrase in the letter being like avoid your in-laws.
Dr. Stacey Clardy: Rough. Poor in-laws. Everybody's an in-law. Yeah, no, same. Going back to your original case and the things that are going to perturb all of us deeply about that, being that the onset was not dramatic, this was not a patient that landed in the ICU after going out hiking, what are you doing now? What do you advise we do when someone on an anti-CD20 therapy or other significant immunosuppression develops otherwise unexplained cognitive or behavioral decline? What's the one thing you really want us to learn and do differently after that particular presentation of a virus?
Dr. Justin Abbatemarco: Some themes that we've hit on and things I've incorporated in my practice is that moving away from these traditional risk factors that I would've previously associated with CD20s, so age, time on therapy, their disability, their IgG levels. Yes, those are some markers that we could use, but I will not be married to those to think about their risk of infections on these classes of medications. I think two, the CD20s can really mask the degree of inflammation that we can see or the serologies. And so being a little mindful of how we incorporate testing and maybe a little sooner metagenomic next gen sequencing if we can get that in the spinal fluid. And again, just having this higher on that differential and being a little bit more mindful about prevention, and all the different ways we talked about. Those are some things that we're really going to think about, and hopefully help our patients and family members moving forward.
Dr. Stacey Clardy: Yeah, these are great points. And now you've just made me think of something else. All these ghosts of patients past good syndrome. I know you're familiar with that, but again, it's not just the CD20 patients, it's these patients walking around who don't know that their immune system is not normal. And I've been involved in the care of several folks now with good syndrome. And so what is that? They don't teach us what that is in neurology, but it's an immune deficiency. And these folks can also be hovering around our clinics with things like myasthenia gravis and other unusual autoimmune conditions. And those are the patients that really drove home for me asking the infectious exposure questions, the infectious history, sinus infections, bronchitis, urine infections, skin infections, the hangnail that didn't heal, or, oh, just a little bit of MRSA, but it healed up, those things all together because those patients essentially have really an undiagnosed immune deficiency that causes frequent infections that some may not recognize are too frequent, superimposed with autoimmunity. And if we don't pick up on them because they come in and we're going to treat the autoimmunity, goodness, we've really doomed them to some awful things too. And so there are other reports out there, other than the Potosi virus, and some of those reports are in these patients of just really being unable to clear viruses chronically from their brain. So it really is a great example of caution for me on these medications, but also just listening to those patients and caution in any patient that comes in where it doesn't quite sound right. As you said, she was young. There was nothing right out of the gate except why the cognitive changes, why this stuff. And I think they're out there more than we realize. CD20 agents are going to bring them to the forefront, but this still occurs naturally as well.
Dr. Justin Abbatemarco: I'm guessing you picked up some of those cases, like good syndrome, by doing testing before you started immunosuppression?
Dr. Stacey Clardy: I have. So things to think about, especially, we didn't even talk about this, but measles titers and measles vaccination, what do we do with that in rituximab? That's a live vaccine. So we can check our patient's IgG, which is again only half the story. For example, you may get a low IgG, and they may actually have some immunity on that titer because, depending on the rituximab or the other B-cell agents, how long they've been on it, but it's a good reminder. That's a discussion that I've been incorporating as well, especially in the last one to two years. What's your measles status? Were you vaccinated? How many times were you vaccinated? How old are you? Meaning, how did that inform the vaccine strategy when you were younger if you did? And if you didn't, again, that extra layer of, oh, this is serious. Are you a teacher? Are you a healthcare worker? What area of the world do you live in, and how much are we seeing resurgence of measles? I don't know if that's come up in your clinic, too.
Dr. Justin Abbatemarco: It has, and I agree. It's just such a difficult conversation. People aren't usually aware. I appreciate your comment. The measles lab test is imperfect, so that's not a great marker. And then a live vaccination, have to be thinking about this before you open this door, maybe a Pandora's box with these immunosuppressive medications, but it's such a difficult topic to explore with patients and their families.
Dr. Stacey Clardy: The one we have to explore. That much is clear. That's our job. If we're ever writing a script for an immunotherapy, we've got to discuss all of these things and be thoughtful and give patients references for them. In the era of the electronic medical record, this is very easy to incorporate all of these things. Justin, it has been a great review for me and learning. Thank you for walking us through all these scenarios, things to think about. This helps me to continue to shape my approach in clinic, and this two-part podcast has been thought-provoking. So thank you for that, and thank you for publishing your paper. The title again is Establishing Potosi Virus as a Human Pathogen: Fatal Neuroinvasive Disease in a B-Cell Depleted Patient. It is in Neurology. Thanks, Justin. This is Stacey Clardy, your podcast editor. If you've enjoyed the podcast, please take a few moments to subscribe, rate, and review the Neurology Podcast through Apple Podcasts, Google Podcasts, Spotify, or wherever you listen. And remember, you can always head to neurology.org/podcast for our full list of past episodes, or you can also search by keyword in your podcast app for any neurology-specific topics you want to learn about.